QTTB Company Profile and Key Details

NASDAQ : QTTB

Q32 Bio

$10.91

-0.19-1.71%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Q32 Bio Inc. (QTTB) stock surged +2.38%, trading at $11.17 on NASDAQ, up from the previous close of $10.91. The stock opened at $10.77, fluctuating between $10.51 and $11.29 in the recent session.

Stock Snapshot

10.91

Prev. Close

332.46M

Market Cap

10.51

Day Low

5.4

P/E Ratio

2.07

EPS (TTM)

N/A

Cash Flow per Share

10.77

Open

29.76M

Number of Shares

11.29

Day High

36.58%

Free Float in %

N/A

Book Value

602.09K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 14, 2026	10.96	11.28	10.63	10.91	870.61K
Sep 11, 2026	10.82	11.27	10.45	11.10	1.82M
Sep 10, 2026	11.00	11.08	10.54	10.72	937.62K
Sep 09, 2026	11.61	11.95	11.07	11.14	488.53K
Sep 08, 2026	12.00	12.00	11.57	11.69	592.92K
Sep 04, 2026	12.60	12.70	11.50	11.99	851.34K
Sep 03, 2026	13.52	13.59	12.74	12.80	491.43K
Sep 02, 2026	14.42	14.55	13.35	13.59	433.32K
Sep 01, 2026	14.77	14.77	14.18	14.36	331.26K
Aug 31, 2026	14.85	15.32	14.75	14.87	348.35K
Aug 28, 2026	15.91	16.25	14.92	15.03	353.14K
Aug 27, 2026	16.08	16.30	15.93	16.15	198.92K
Aug 26, 2026	16.13	16.52	15.80	16.18	327.06K
Aug 25, 2026	16.36	16.98	16.06	16.32	598.21K
Aug 24, 2026	16.50	16.66	15.50	16.36	690.85K
Aug 21, 2026	15.89	16.29	15.72	15.97	341.35K
Aug 20, 2026	15.80	16.15	15.51	15.86	388.59K
Aug 19, 2026	15.56	15.93	15.25	15.84	266.88K
Aug 18, 2026	15.65	16.04	15.04	15.29	319.35K
Aug 17, 2026	15.18	16.05	15.18	15.95	293.04K

Contact Details

Waltham, MA 02451

United States

https://www.q32bio.com 781 999 0232

About Company

Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.

Stock Peers

ARGX

6.15+0.62%

argenx SE$990.54 REGN

12.25+1.57%

Regeneron Pharmaceuticals, Inc.$793.74 MDGL

5.57+1.04%

Madrigal Pharmaceuticals, Inc.$540.06 VRTX

4.07+0.79%

Vertex Pharmaceuticals Incorporated$519.51 UTHR

5.59+1.12%

United Therapeutics Corporation$502.70 ONC

7.32+2.11%

BeOne Medicines AG$353.83 KRYS

-6.97-2.01%

Krystal Biotech, Inc.$340.03 PRAX

-4.03-1.20%

Praxis Precision Medicines, Inc.$330.55 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

-3.82-1.34%

Ligand Pharmaceuticals Incorporated$280.65

Company Overview

Q32 Bio Inc. (NASDAQ:QTTB) closed at $11.17 USD, gaining $0.26 (2.38%) from the previous close of $10.91. The stock is currently mid-range between its 52-week high and low $1.69 and $23.57. With a market capitalization of about $332.46 million, Q32 Bio Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.33). Key stats such as the average daily volume over the past year has been around 1.18 million shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Q32 Bio Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jodie Pope Morrison, the company employs approximately 22 people and listed since March 28, 2018. Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses.

Technical Performance

QTTB has shown sold momentum, gaining 7.97% over the past week and 23.97% over the past quarter, though year-to-date performance is up 18.37%. Short-term trend indicators are bearishly aligned (SMA20 14.16%, SMA50 27.24%, SMA200 86.11%). The stock’s 14-day RSI is 63.58 (firm momentum), while the ATR of 0.39 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.27% below its high and over 253.9% above its low. Average 10-day trading volume of 942.79 thousand shares is below the 3-month average of 1.16 million, indicating normal recent market interest.

Valuation Metrics

Q32 Bio Inc. trades at a P/E ratio of 3.94, slightly below the S&P 500 average, with a price-to-sales ratio of 6.09 and a price-to-book ratio of 1.46 suggesting the stock is closer to book value. The P/FCF stands at -16.5, also below market averages.

Dividend & Fair Value

Q32 Bio Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.98. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Q32 Bio Inc. generated EPS of -$3.45 over the past year. Five-year average earnings growth is 31.75%. Wall Street analysts project EPS growth of 15.19% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $66.00 to $13.00. The high target offers 504.95% upside. The low target suggests 19.16% downside. The mean target is $30.86. This offers 182.86% upside. Q32 Bio Inc. earnings surprise history is frequent misses against expectations. The quarter that ended August 05, 2026, missed forecasts by -9.46%. The prior quarter beat by -20.59%. Over the last six quarters, Apple has recorded several small beats. These include -26.83% in May 08, 2025.

Shareholding & Insider Activity

Q32 Bio Inc. has 29.77 million shares outstanding. The public float is 14.47 million shares, elevated short interest at 14.32% of float. This equals 3.00 million shares. The short ratio is 1.28 days. Institutional investors hold 112.25% of the float. Insiders own 4.56%. ORBIMED ADVISORS LLC holds 625.00 thousand shares, Xu Diyong has 625.00 thousand shares and Morrison Jodie Pope has 343.26 thousand shares. Over the past six months, insider transactions show net selling. They sold 16.62 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Q32 Bio has not generated any revenue.
On valuation metrics, Q32 Bio trades at a P/E of 3.94, P/S of 6.09 and P/B of 1.46. The current ratio is 20.30 and quick ratio is 20.30. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -6704.05 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.05, supported by a cash flow-to-debt ratio of -3.74.

Price Forecast & Outlook

Our AI price prediction model suggests that Q32 Bio Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -45.1%, with price expected at $5.99 by September 28, 2026, within a range of $5.22 to $6.75 3-Month Outlook: Projected rise of 167.28%, reaching $29.16 by December 11, 2026, with a range of $28.91 to $29.42. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 14, 2027, within a range of $0.00 to $1.90.

Key Takeaways

Q32 Bio Inc. (NASDAQ:QTTB) shares are up 18.37% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Q32 Bio Inc. trading at a premium to the broader market with a P/E of 3.94. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $28.39, suggesting 160.22% upside. Our AI forecast model points to short-term weakness (-45.1% over two weeks), a medium-term rise (167.28% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Q32 Bio Inc. (QTTB) stock price?

Q32 Bio Inc. (NASDAQ: QTTB) stock price is $11.17 in the last trading session. During the trading session, QTTB stock reached the peak price of $11.29 while $10.51 was the lowest point it dropped to. The percentage change in QTTB stock occurred in the recent session was 2.38% while the dollar amount for the price change in QTTB stock was $0.26.

QTTB's industry and sector of operation?

The NASDAQ listed QTTB is part of Biotechnology industry that operates in the broader Healthcare sector. Q32 Bio Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of QTTB?

No Data

How QTTB did perform over past 52-week?

QTTB's closing price is 545.56% higher than its 52-week low of $1.69 where as its distance from 52-week high of $23.57 is -53.71%.

How many employees does QTTB have?

Number of QTTB employees currently stands at 22.

Link for QTTB official website?

Official Website of QTTB is: https://www.q32bio.com

How do I contact QTTB?

QTTB could be contacted at phone 781 999 0232 and can also be accessed through its website. QTTB operates from 830 Winter Street, Waltham, MA 02451, United States.

How many shares of QTTB are traded daily?

QTTB stock volume for the day was 602.09K shares. The average number of QTTB shares traded daily for last 3 months was 1.18M.

What is the market cap of QTTB currently?

The market value of QTTB currently stands at $332.46M with its latest stock price at $11.17 and 29.76M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	22
Beta	-0.33
Sales or Revenue	N/A
5Y Sales Change%	-1.166%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

QTTB Company Profile and Key Details

Q32 Bio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Valuation Metrics

Company Overview

Dividend & Fair Value

Financial & Profitability Overview

Shareholding & Insider Activity

Key Takeaways

Price Forecast & Outlook